Gilead Sciences is een biotech-pionier in antivirale therapieën, met baanbrekende behandelingen voor hiv en hepatitis C, en breidt zijn oncologiepijplijn uit door overnames en interne ontwikkeling van celtherapieën en antilichaam-geneesmiddelconjugaten.
Gilead Sciences betaalt een groeiend kwartaaldividend ondersteund door robuste vrije kasstroom, en biedt beleggers een zeldzame combinatie van biotech-niveau innovatie met de inkomsteneigenschappen die doorgaans met volwassen farmaceutische bedrijven worden geassocieerd.
Gilead Sciences is een groot farmaceutisch bedrijf met een dominante positie in HIV-behandeling en -preventie, dat miljarden aan jaarlijkse inkomsten genereert uit marktleidende antiretrovirale therapieën, waaronder Biktarvy.
Data updated Feb 15 · Source: Twelve Data
Gilead Sciences has delivered exceptional performance over the past year, with shares surging 50% and now trading near 52-week highs. The company's dominant HIV franchise provides a durable revenue base, while its oncology pipeline"anchored by Trodelvy and the transformative lenacapavir long-acting HIV treatment"offers meaningful growth catalysts. At a P/E of 17.81 with EPS of $8.70, the valuation remains reasonable for a large-cap pharma name, though the recent sharp rally (36% in 90 days) suggests much good news is already priced in. Gilead's dividend yield (~3%) supported by strong free cash flow generation makes it attractive for income investors, though payout growth has been modest. The bull case centers on lenacapavir's blockbuster potential in both HIV prevention and treatment, plus expanding oncology revenues. Bear case risks include eventual HIV franchise maturation, pricing pressures, and pipeline execution risk. The stock trading well above its 50-day moving average ($130.17) warrants caution on entry timing, but the fundamental story remains compelling for long-term holders.
Gilead Sciences is exhibiting significant market strength, currently trading near its 52-week high of $157.29 with a reasonable P/E ratio of 19.00. As a global leader in virology, the company's dominant HIV portfolio generates substantial cash flow, underpinning its reputation as a reliable income generator in the biotech sector. The investment thesis is further supported by a successful strategic pivot into oncology, diversifying revenue streams beyond its legacy antiviral business. With a robust EPS of $8.20, Gilead demonstrates strong operational efficiency. However, the stock is trading significantly above its 50-day moving average of $129.00, which may suggest the valuation is becoming full in the short term. While competitive risks in the oncology space remain, Gilead presents a balanced profile for investors seeking a blend of growth potential and dividend stability.
Latest from Otrai
A stock index is a single number that summarizes the price action of a basket of companies. The S&P 500 tracks roughly 500 large US firms, the Nasdaq-100 tracks the 100 largest non-financial names on the Nasdaq exchange, and the Dow Jones Industrial Average follows 30 blue-chip stocks.
The Greeks explain why an option costs what it costs and how that price changes when the stock moves, time passes, and volatility shifts. Delta, Gamma, Theta, and Vega, made accessible.
Chart patterns are the most recognizable part of technical analysis and the most misunderstood. Most fail or break out the wrong way before reversing. This guide covers head and shoulders, double tops and bottoms, triangles, and flags — with realistic reliability, target measurement, and false-breakout confirmation.
Elke trader heeft een strategie die in hun hoofd geweldig eruit ziet. Backtesting is hoe je ontdekt of het werkelijk werkt. Hier is hoe je strategieën correct test, welke statistieken belangrijk zijn en waarom de meeste backtestresultaten te mooi om waar te zijn zijn.
Powered by Rexiew